Moreover, considering there are some widely-used biomarkers for lung cancer such as EGFR, KRAS, and PD-L1, combination of these factors with ZHX factors may provide more accurate and precise methods for prediction of patient survival. This evidence concerns the gene KRAS and lung carcinoma.